DNLI Q4 2019 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-96.3% YoY

Gross Profit

$5M100.0% margin

Operating Income

-$58M-1236.3% margin

Net Income

-$54M-1156.4% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

-65.7%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$50M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$553M

Total Liabilities

$158M

Stockholders' Equity

$395M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$126M	-96.3%
Gross Profit	$5M	$126M	-96.3%
Operating Income	-$58M	$75M	-177.3%
Net Income	-$54M	$78M	-169.7%